Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

27.3%

6 terminated/withdrawn out of 22 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

18%

4 trials in Phase 3/4

Results Transparency

100%

12 of 12 completed trials have results

Key Signals

1 recruiting12 with results

Enrollment Performance

Analytics

Phase 2

15(71.4%)

Phase 3

4(19.0%)

Phase 1

2(9.5%)

21Total

Phase 2(15)

Phase 3(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT05229991Phase 3Completed

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Role: collaborator

NCT04727424Phase 3Recruiting

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Role: collaborator

NCT05070364Phase 3Unknown

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Role: lead

NCT02527707Phase 2Completed

Titrating-Dose of Lonafarnib in Combination With Ritonavir

Role: lead

NCT04652479Phase 2Completed

Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia

Role: collaborator

NCT03719313Phase 3Completed

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Role: lead

NCT02664558Phase 2Completed

A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Role: lead

NCT02430194Phase 2Completed

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Role: lead

NCT00916747Phase 2Unknown

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Role: collaborator

NCT02700529Phase 2Completed

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Role: lead

NCT02736149Phase 2Terminated

Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Role: lead

NCT02765802Phase 2Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

Role: lead

NCT02430181Phase 2Completed

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Role: lead

NCT04343976Phase 2Terminated

Pegylated Interferon Lambda Treatment for COVID-19

Role: collaborator

NCT03373435Phase 2Completed

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Role: lead

NCT04344600Phase 2Terminated

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

Role: collaborator

NCT00945880Phase 1Completed

Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive

Role: lead

NCT03895528Unknown

Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy

Role: lead

NCT04388709Phase 2Withdrawn

Interferon Lambda Therapy for COVID-19

Role: collaborator

NCT02968641Phase 2Withdrawn

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV

Role: lead